Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. MGC Pharmaceuticals Limited
  6. Summary
    MXC   AU000000MXC6

MGC PHARMACEUTICALS LIMITED

(MXC)
  Report
End-of-day quote. End-of-day quote Australian Stock Exchange - 11/29
0.041 AUD   -6.82%
06:10aOmicron Variant Seen Posing Threat to Pound
DJ
05:10aFTSE 100 Falls Sharply as Omicron Fears Reemerge
DJ
04:05aEasyJet Shares Rebound From Sharp Early Losses; Results Meet Hopes
DJ
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Stock Exchange
11/23/2021 11/24/2021 11/25/2021 11/26/2021 11/29/2021 Date
0.046 0.045 0.045 0.044 0.041 Last
2388132 2068229 1059136 990093 2614882 Volume
+2.22% -2.17% 0.00% -2.22% -6.82% Change
Estimated financial data (e)
Sales 2022 20,2 M 14,4 M 14,4 M
Net income 2022 -7,42 M -5,29 M -5,29 M
Net Debt 2022 7,90 M 5,63 M 5,63 M
P/E ratio 2022 -14,6x
Yield 2022 -
Sales 2023 40,3 M 28,7 M 28,7 M
Net income 2023 - - -
Net Debt 2023 8,50 M 6,05 M 6,05 M
P/E ratio 2023 -
Yield 2023 -
Capitalization 99,3 M 70,7 M 70,8 M
EV / Sales 2022 5,31x
EV / Sales 2023 2,68x
Nbr of Employees -
Free-Float 93,9%
More Financials
Company
MGC Pharmaceuticals Limited is an Australia-based biopharma company. The Company is primarily focused on producing standardized, phytocannabinoid and plant-derived medicines. The Company’s Nature to Medicine strategy comprises the entire supply chain, from botanical research, to develop new strains of Cannabis Sativa, preclinical and clinical research, product manufacturing, distribution, as well as the... 
Sector
Pharmaceuticals
Calendar
03/02Earnings Release
More about the company
Ratings of MGC Pharmaceuticals Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about MGC PHARMACEUTICALS LIMITED
06:10aOmicron Variant Seen Posing Threat to Pound
DJ
05:10aFTSE 100 Falls Sharply as Omicron Fears Reemerge
DJ
04:05aEasyJet Shares Rebound From Sharp Early Losses; Results Meet Hopes
DJ
11/26MGC Pharmaceuticals Completes Food Supplement Production Order for European Distributor
MT
11/24MGC Pharmaceuticals Limited Completes Production of AUD 1 Million ArtemiC Order from SP..
CI
11/24FTSE 100 Closes Up as Intertek, Oil Companies Rise
DJ
11/24London Shares Flat, Intertek Top FTSE 100 Rsers
DJ
11/24MGC Pharmaceuticals Ltd Completes Delivery of the ?650,000 (AUD 1,000,000) ArtemiCTM Or..
CI
11/23MGC PHARMACEUTICALS : Application for quotation of securities - MXC
PU
11/22MGC Pharmaceuticals Limited Announces Full USD 750,000 Cash Deposit Received for First ..
CI
11/12Notification regarding unquoted securities - MXC
PU
11/02MGC Pharmaceuticals Limited Announces the Completion of the Construction and Implementa..
CI
11/01Israel's Health Ministry Approves MGC Pharma's Dosing Study for COVID-19 Drug
MT
11/01Israeli Ministry of Health Approves MGC Pharmaceuticals Limited's Dosing Study for Cime..
CI
11/01FTSE 100 Closes Up on Positive Momentum, Easing Supply Crunch Fears
DJ
More news
News in other languages on MGC PHARMACEUTICALS LIMITED
11/26MGC Pharmaceuticals achève une commande de production de compléments alimentaires pour ..
10/07MGC Pharmaceuticals obtient un bon de commande de 3 millions de dollars pour un médicam..
09/30MGC Pharmaceuticals reçoit la première commande de fourniture de CimetrA
09/13Le médicament contre l'épilepsie réfractaire de MGC Pharmaceuticals obtient un permis d..
09/02MGC Pharmaceuticals bondit de 11% après avoir obtenu un permis d'importation indien pou..
More news
Chart MGC PHARMACEUTICALS LIMITED
Duration : Period :
MGC Pharmaceuticals Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MGC PHARMACEUTICALS LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 0,04 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Roby Reuven Zomer Chief Executive Officer, MD & Director
Brett Anthony Mitchell Executive Chairman
Amir Polak Chief Technology Officer
Stephen B. Parker Senior Independent Director
Evan Hayes Independent Non-Executive Director